GISTs

What are Gastrointestinal Stromal Tumours? 

Gastrointestinal Stromal Tumours (GISTs) are rare tumours that develop in the gastrointestinal (GI) tract. They originate from specialised cells in the digestive system known as interstitial cells of Cajal, which help regulate the movement of food through the stomach and intestines. These cells act as the “pacemakers” of the digestive system, coordinating the muscular contractions that move food through the gastrointestinal tract.


GISTs are classified as soft tissue sarcomas, meaning they arise from connective tissue rather than from the lining of the digestive organs. They can occur anywhere along the gastrointestinal tract, but most commonly develop in:

  • Stomach: Around 60–70% of cases occur in the stomach.
  • Small intestine: Approximately 20–30% develop in the small bowel.
  • Oesophagus, colon, or rectum: Less commonly, they may arise in other parts of the digestive tract.
  • Abdominal cavity: In rare cases, they may develop in nearby tissues outside the digestive organs.


These tumours vary widely in behaviour. Some are slow-growing and relatively harmless, while others can become malignant (cancerous) and spread to other parts of the body, most commonly the liver or abdominal lining.


Impact of GISTs on Anatomy and Health

GISTs affect the body primarily by growing within the wall of the gastrointestinal tract and potentially interfering with normal digestive function. Because they originate from the connective tissue of the digestive organs, they often grow outward from the wall of the stomach or intestines rather than directly into the inner lining.


The impact on anatomy and health depends on several factors, including the size of the tumour, its location, and whether it has spread to other organs.


Some of the ways GIST tumours can affect the body include:

  • Disruption of Digestive Function: Tumours may interfere with the normal movement of food through the digestive tract, leading to discomfort, fullness, or difficulty eating.
  • Bleeding within the Gastrointestinal Tract: As a tumour grows, it may erode into nearby blood vessels, causing internal bleeding that may lead to anaemia.
  • Obstruction of the Digestive Tract: Larger tumours may partially block the stomach or intestines, preventing food from passing normally.
  • Pressure on Nearby Organs: If the tumour grows outward into the abdominal cavity, it may press against surrounding organs such as the liver, pancreas, or intestines.
  • Spread to Other Organs: In more aggressive cases, GIST tumours may metastasise, most commonly to the liver or the peritoneum (lining of the abdominal cavity).
  • Nutritional Problems: Digestive disturbances, bleeding, or obstruction may result in weight loss, fatigue, or nutritional deficiencies.


Many smaller GIST tumours cause few or no symptoms and are sometimes discovered incidentally during imaging tests or endoscopy performed for unrelated reasons. Larger tumours are more likely to produce symptoms and require treatment.


Risk Factors and Causes of GISTs

Although GISTs are uncommon, certain individuals are at higher risk of developing them.


Risk factors include:

  • Age: GISTs are most commonly diagnosed in adults over age 50, though they can occur at any age.
  • Gender: Both men and women can develop GIST, though some studies suggest a slightly higher incidence in men.
  • Genetic Mutations: Many GISTs arise from mutations in specific genes, particularly KIT and PDGFRA, which regulate cell growth.
  • Inherited Genetic Syndromes: A small proportion of GISTs are associated with hereditary conditions, including:
  • Neurofibromatosis type 1 (NF1)
  • Carney-Stratakis syndrome
  • Familial GIST syndrome
  • Family History: Individuals with rare familial genetic mutations may have multiple GISTs or develop them at a younger age.
  • Previous Tumours of the Digestive System: Although uncommon, certain patients with a history of gastrointestinal tumours may be monitored more closely.


For most people diagnosed with GIST, however, there is no clear lifestyle or environmental cause, and the tumour develops sporadically.


Symptoms of GISTs

Small tumours may not produce any symptoms and are often detected incidentally during imaging or endoscopic examinations.


When symptoms do occur, they may include:

  • Abdominal pain or discomfort: Often vague or persistent.
  • Gastrointestinal bleeding: This may appear as vomiting blood or passing black, tarry stools.
  • Anaemia: Chronic bleeding may lead to fatigue, weakness, or shortness of breath.
  • Early satiety: Feeling full quickly after eating.
  • Abdominal swelling or a palpable mass: Larger tumours may be felt during a physical examination.
  • Nausea or vomiting: Particularly if the tumour obstructs the digestive tract.
  • Difficulty swallowing: When tumours occur in the oesophagus.
  • Unexplained weight loss: May occur with advanced disease.


Because these symptoms can also occur with many other digestive conditions, medical evaluation is important for accurate diagnosis.


Preventing GISTs

Currently, there is no proven method to completely prevent GISTs, as most cases arise from spontaneous genetic mutations that cannot be predicted or avoided.


However, certain strategies may help with early detection and risk management.

  • Genetic Counselling: Individuals with a family history of hereditary GIST syndromes may benefit from genetic testing and counselling.
  • Regular Medical Monitoring: Patients with known genetic conditions, such as Neurofibromatosis type 1, may undergo periodic imaging or gastrointestinal evaluations.
  • Prompt Investigation of Symptoms: Early evaluation of persistent abdominal pain, unexplained bleeding, or anaemia can help detect tumours at an earlier stage.
  • Routine Gastrointestinal Screening: Endoscopy or imaging performed for other digestive conditions may identify small GIST tumours before symptoms develop.
  • General Digestive Health Awareness: Maintaining regular medical check-ups and discussing unusual digestive symptoms with a healthcare provider can assist in early diagnosis.


Because GIST tumours are uncommon and often develop without warning, early detection and timely treatment remain the most effective strategies for managing the condition.


Types of GISTs

GISTsmay be classified according to genetic mutation, including:

  • KIT mutation-positive GIST: The most common subtype.
  • PDGFRA mutation-positive GIST: Often found in gastric tumours and may behave differently.
  • Wild-type GIST: Tumours without KIT or PDGFRA mutations.
  • SDH-deficient GIST: Rare tumours that often occur in younger individuals.


Stages of GIST Tumours

Unlike many other cancers, lymph node spread is uncommon in GIST tumours. Instead, they are more likely to spread to the liver or the peritoneum (lining of the abdominal cavity).


The general staging categories include:

  • Stage I – Localised Small Tumour: The tumour is small and confined to the gastrointestinal tract. The risk of spreading is low, and surgical removal is often highly effective.
  • Stage II – Larger Localised Tumour: The tumour is larger but still confined to the digestive organ where it began. The growth rate may still be relatively low.
  • Stage III – High-Risk Localised Tumour: The tumour is large or has a high mitotic rate, indicating faster cell division. While it may not yet have spread, it carries a higher risk of recurrence or metastasis.
  • Stage IV – Metastatic Disease: The tumour has spread beyond the gastrointestinal tract to distant organs, most commonly the liver or the lining of the abdominal cavity.


In addition to staging, doctors also assess the risk of recurrence, which takes into account tumour size, location, and cellular activity. This risk assessment helps determine whether additional treatments, such as targeted therapy, are required after surgery.


Diagnosis of GISTs

Because many GIST tumours grow slowly and may not initially cause symptoms, they are sometimes discovered during tests performed for other digestive conditions.


Common diagnostic methods include:

  • Medical History and Physical Examination: A doctor will evaluate symptoms such as abdominal pain, bleeding, fatigue, or unexplained weight loss.
  • Endoscopy: A flexible tube with a camera is inserted through the mouth to examine the oesophagus, stomach, and upper small intestine. This allows doctors to detect abnormal masses or bleeding.
  • Endoscopic Ultrasound (EUS): This specialised procedure combines endoscopy with ultrasound imaging to examine the layers of the gastrointestinal wall and determine the depth of tumour growth.
  • Computed Tomography (CT) Scan: CT imaging is one of the most important tools for diagnosing and staging GIST tumours. It helps determine tumour size, location, and whether it has spread to nearby organs.
  • Magnetic Resonance Imaging (MRI): MRI may be used in certain cases, particularly for tumours located in the rectum or liver.
  • Biopsy: A small tissue sample may be taken from the tumour and analysed in a laboratory. This confirms the diagnosis and identifies specific genetic mutations such as KIT or PDGFRA.
  • Immunohistochemistry Testing: Specialised laboratory tests detect markers such as CD117 (KIT protein), which is present in most GIST tumours.


These diagnostic steps allow doctors to confirm the presence of a GIST tumour and develop an appropriate treatment plan.


Treatment for GISTs

The primary treatment options include:

  • Surgical Removal:  Surgery is the main treatment for localised GISTs. The goal is to completely remove the tumour with clear margins while preserving as much normal digestive function as possible. Minimally invasive techniques such as laparoscopic surgery may be used in suitable cases.
  • Targeted Therapy (Tyrosine Kinase Inhibitors): Medications such as imatinib are designed to block abnormal signalling pathways caused by KIT or PDGFRA mutations. These drugs may be used:
  • Before surgery to shrink large tumours
  • After surgery to reduce recurrence risk
  • As primary treatment for metastatic disease
  • Adjuvant Therapy: Targeted medications may be prescribed after surgery for patients with higher-risk tumours to prevent recurrence.
  • Treatment for Metastatic Disease: If the tumour has spread, targeted therapy is usually the first-line treatment. Surgery may still be considered in selected cases.
  • Clinical Trials and Emerging Therapies: New targeted treatments and combination therapies are being developed for patients who do not respond to standard medications.


Unlike many other cancers, traditional chemotherapy and radiotherapy are generally less effective for GISTs.


What if GISTs are Untreated?

If a GIST is left untreated, the tumour may continue to grow and cause increasing complications over time. The severity of these complications depends on the tumour’s size, location, and biological behaviour.


Possible consequences include:

  • Tumour Growth
  • Gastrointestinal Bleeding
  • Obstruction of the Digestive Tract
  • Tumour Rupture
  • Progressive Weight Loss and Weakness



Early diagnosis and treatment significantly improve outcomes for patients with GIST tumours. In many cases, surgical removal combined with targeted therapy can control the disease effectively and reduce the risk of recurrence.

▲TOP